

Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)-PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

<https://marketpublishers.com/r/R9C902B6A81CEN.html>

Date: September 2025

Pages: 313

Price: US\$ 4,950.00 (Single User License)

ID: R9C902B6A81CEN

Abstracts

The global radioligand therapy market is projected to reach USD 10.91 billion by 2035 from an estimated USD 3.15 billion in 2025, at a CAGR of 13.2% during the forecast period. The growth of the radioligand therapy market is majorly driven by increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, rising adoption of PSMA and SSTR PET imaging for patient selection, and expanding reimbursement coverage supporting broader patient access.

By target, the prostate-specific membrane antigen segment accounted for the largest market share in 2024.

Based on target, the market is categorized into Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), and other targets. The Prostate-Specific Membrane Antigen (PSMA) segment accounted for the largest share of the market in 2024. The large share of this segment is attributed to its high expression in prostate cancer cells and its minimal presence in normal tissues. This makes PSMA an ideal biomarker for precision oncology, enabling accurate patient selection and effective therapy delivery. The success of PSMA-targeted treatments, such as Pluvicto (lutetium-177 vipivotide tetraxetan), has reinforced its dominance, particularly in metastatic castration-resistant prostate cancer (mCRPC).

By product, the Lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market in 2024.

By product, the market is segmented into Lutetium-177 Vipivotide Tetraxetan, Lutetium-177 Dotatate, Radium-223 Dichloride, [LU-177]-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU Rosopatamab Tetraxetan), Alphamedix (???)PB-DOTAMTATE), 67CU-SAR-BISPSMA, and other products. In 2024, the lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market. Developed and commercialized by Novartis, Lutetium-177 vipivotide tetraxetan (Pluvicto) targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed in prostate cancer cells, making it a precision therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Since its FDA and EMA approvals, the therapy has become widely adopted due to its ability to extend survival and improve quality of life in patients with limited treatment options. Its use of lutetium-177 enables targeted beta radiation delivery, sparing surrounding healthy tissues while maximizing tumor control.

By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the rising cancer incidence, improvements in healthcare infrastructure, and increasing awareness of precision oncology solutions. Countries such as China, Japan, South Korea, India, and Australia are witnessing the growing adoption of nuclear medicine, which is supported by expanding diagnostic capabilities and investments in theragnostic. Governments & private institutions are actively investing in isotope production facilities, addressing long-standing supply challenges for key isotopes like lutetium-177 and actinium-225, essential for commercialized and pipeline RLT products. Regulatory authorities in the region also show greater receptivity to radiopharmaceutical approvals, creating a favourable environment for clinical development and faster patient access.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side- 30%

By Designation: Managers- 45%, CXO and Directors- 30%, and Executives-

25%

By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%

Key Companies

The key players in the radioligand therapy market include Novartis AG (Switzerland), Bayer AG (Germany), Curium US LLC (US), Eli Lilly and Company (US), AstraZeneca plc (UK), Progenics Pharmaceuticals, Inc. (US), Ariceum Therapeutics GmbH (Germany), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics, Inc. (US), Orano Med SAS (France), Actinium Pharmaceuticals, Inc. (US), Perspective Therapeutics, Inc. (US), Clarity Pharmaceuticals Ltd. (Australia), and Radiopharm Theranostics Ltd. (Australia), among others.

Research Coverage

This research report categorizes the radioligand therapy market, by product [Lutetium-177 vipivotide tetraxetan, LUTETIUM-177 DOTATATE, Radium-223 dichloride, (LU-177)-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU ROSOPATAMAB TETRAXETAN), ALPHAMEDIX (???PB-DOTAMTATE), 67CU-SAR-BISPSMA, and other products), target (PSMA, SSTR, and other targets), indication (prostate cancer, neuroendocrine tumors, and other indications), and end user (tertiary care academic/comprehensive cancer centers, specialized nuclear medicine centers, and other end user), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa).

The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the radioligand therapy market. A thorough analysis of the key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements: new approvals/launches, collaborations, acquisitions, and recent developments associated with the radioligand therapy market.

Reasons to buy this report

The report will help market leaders and new entrants by providing the closest

approximations of the revenue numbers for the radioligand therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, the rising adoption of PSMA and SSTR PET imaging for patient selection. Expanding reimbursement coverage supporting broader patient access), restraints (Isotope scarcity for Lu-177 and Ac-225 creating supply bottlenecks, complex regulatory requirements for handling & licensing radioactive materials, logistical hurdles & half-life constraints limiting distribution), opportunities [advancements of alpha therapies (Ac-225, Pb-212) with strong clinical potential, expansion into earlier-line and adjuvant use, broadening eligible populations, combination regimens with immuno-oncology, PARP inhibitors, and other targeted agents), and challenges (reactor outages and geopolitical risks impacting isotope production & supply chains and the growing competition from alternative modalities such as ADCs and bispecific antibodies)

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the radioligand therapy market

Market Development: Comprehensive information about lucrative markets across varied regions

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the radioligand therapy market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the radioligand therapy market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
 - 1.3.2 INCLUSIONS AND EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Objectives of secondary research
 - 2.1.1.2 Key data from secondary sources
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Breakdown of primaries
 - 2.1.2.2 Key objectives of primary research
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 GLOBAL MARKET ESTIMATION
 - 2.2.1.1 Company revenue analysis (Bottom-up approach)
 - 2.2.1.2 Revenue share analysis
 - 2.2.1.3 MnM repository analysis
 - 2.2.1.4 Primary interviews
 - 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
 - 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
- 2.3 GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

- 3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS

- 3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES
- 3.1.2 ESTABLISHED MARKET LEADERS
- 3.1.3 CDMOS AND CROS

4 PREMIUM INSIGHTS

- 4.1 RADIOLIGAND THERAPY MARKET OVERVIEW
- 4.2 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT AND COUNTRY, 2025
- 4.3 RADIOLIGAND THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 RADIOLIGAND THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS
- 4.5 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.6 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT
- 4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE
- 4.8 REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 DRIVERS
 - 5.2.1.1 Increasing approvals and label expansion of RLT products
 - 5.2.1.2 Manufacturing scale-up of Lu-177
 - 5.2.1.3 Rising adoption of prostate-specific membrane antigen and somatostatin receptor PET imaging
 - 5.2.1.4 Expanding reimbursement coverage
 - 5.2.2 RESTRAINTS
 - 5.2.2.1 Isotope supply scarcity
 - 5.2.2.2 Stringent regulatory requirements
 - 5.2.2.3 Logistical hurdles and half-life constraints
 - 5.2.3 OPPORTUNITIES
 - 5.2.3.1 Advancements in alpha therapies
 - 5.2.3.2 Expansion of radioligand therapy into earlier-line and adjuvant settings
 - 5.2.3.3 Combination regimens integrating radioligand therapy
 - 5.2.4 CHALLENGES
 - 5.2.4.1 Reactor outages and geopolitical risks
 - 5.2.4.2 Growing competition from alternative modalities
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 PRICING ANALYSIS

- 5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
- 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 ECOSYSTEM ANALYSIS
- 5.7 INVESTMENT AND FUNDING SCENARIO
- 5.8 TECHNOLOGY ANALYSIS
 - 5.8.1 KEY TECHNOLOGIES
 - 5.8.1.1 Beta-emitting therapeutic radionuclides
 - 5.8.1.2 Alpha-emitting therapeutic radionuclides
 - 5.8.1.3 Targeting ligands
 - 5.8.1.4 Monoclonal antibody-directed radiotherapeutics
 - 5.8.2 COMPLEMENTARY TECHNOLOGIES
 - 5.8.2.1 SPECT/CT and PET/CT
 - 5.8.2.2 Alternative isotopes
 - 5.8.3 ADJACENT TECHNOLOGIES
 - 5.8.3.1 Antibody drug conjugates
 - 5.8.3.2 Bispecific antibodies
- 5.9 KEY CONFERENCES AND EVENTS, 2025–2027
- 5.10 REGULATORY LANDSCAPE
 - 5.10.1 REGULATORY ANALYSIS
 - 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11 PORTER'S FIVE FORCES ANALYSIS
 - 5.11.1 BARGAINING POWER OF SUPPLIERS
 - 5.11.2 BARGAINING POWER OF BUYERS
 - 5.11.3 THREAT OF NEW ENTRANTS
 - 5.11.4 THREAT OF SUBSTITUTES
 - 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.12 KEY STAKEHOLDERS AND BUYING PROCESS
 - 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
 - 5.12.2 BUYING CRITERIA
- 5.13 MACROECONOMICS INDICATORS
 - 5.13.1 HEALTHCARE EXPENDITURE TRENDS
 - 5.13.2 GLOBAL CANCER BURDEN
- 5.14 PIPELINE ANALYSIS
- 5.15 UNMET NEEDS AND WHITE SPACES
- 5.16 IMPACT OF AI/GEN AI ON RADIOLIGAND THERAPY MARKET
 - 5.16.1 INTRODUCTION
 - 5.16.2 MARKET POTENTIAL OF AI IN RADIOLIGAND THERAPY APPLICATIONS

5.16.3 AI USE CASES

5.17 IMPACT OF 2025 US TARIFF

5.17.1 INTRODUCTION

5.17.2 KEY TARIFF RATES

5.17.3 PRICE IMPACT ANALYSIS

5.17.4 IMPACT ON COUNTRY/REGION

5.17.4.1 US

5.17.4.2 Europe

5.17.4.3 Asia Pacific

5.17.4.4 Rest of the World

5.17.5 IMPACT ON MANUFACTURING INDUSTRY

6 RADIOLIGAND THERAPY MARKET, BY PRODUCT

6.1 INTRODUCTION

6.2 LUTETIUM 177 VIPIVOTIDE TETRAXETAN

6.2.1 BROADER REGULATORY ACCEPTANCE AND EXPANDING PAYER COVERAGE TO AID GROWTH

6.3 LUTETIUM-177 DOTATATE

6.3.1 INCREASING RECOGNITION OF LUTETIUM-177 DOTATATE IN TREATING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO BOOST MARKET

6.4 RADIUM-223 DICHLORIDE

6.4.1 INCREASING ADOPTION OF RADIUM-223 DICHLORIDE IN EMERGING MARKETS TO STIMULATE GROWTH

6.5 LU-177 PNT2002

6.5.1 STRONG PHASE III CLINICAL VALIDATION AND STRATEGIC COMMERCIALIZATION PARTNERSHIPS TO SPUR GROWTH

6.6 ¹⁷⁷Lu-PSMA-617

6.6.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO BOLSTER GROWTH

6.7 FPI-2265

6.7.1 EARLY RESPONSE DATA AND SAFETY REASSURANCE TO AMPLIFY GROWTH

6.8 I-131-1095

6.8.1 FAVORABLE DOSIMETRY AND SAFETY PROFILES TO SUSTAIN GROWTH

6.9 TLX591

6.9.1 SIMPLIFIED DOSING REGIMEN AND FAVORABLE TOLERABILITY TO DRIVE MARKET

6.10 ALPHAMEDIX (⁶⁷Zn-DOTAMTATE)

6.10.1 ROBUST EARLY-PHASE EFFICACY AND STRONG COMMERCIALIZATION TO SUPPORT GROWTH

6.11 ⁶⁷Zn-SAR-BISPSMA

6.11.1 ENHANCED LESION UPTAKE & RETENTION AND FAVORABLE TOLERABILITY PROFILE TO FOSTER GROWTH

6.12 OTHER PRODUCTS

7 RADIOLIGAND THERAPY MARKET, BY TARGET

7.1 INTRODUCTION

7.2 PROSTATE-SPECIFIC MEMBRANE ANTIGEN

7.2.1 STRONG BIOLOGICAL RATIONALE, ROBUST CLINICAL OUTCOMES, AND RAPID SCALING OF GLOBAL SUPPLY CHAINS TO PROMOTE GROWTH

7.3 SOMATOSTATIN RECEPTOR

7.3.1 PROVEN EFFICACY IN TREATING NEUROENDOCRINE TUMORS TO EXPEDITE GROWTH

7.4 OTHER TARGETS

8 RADIOLIGAND THERAPY MARKET, BY INDICATION

8.1 INTRODUCTION

8.2 PROSTATE CANCER

8.2.1 EXPANDING TREATMENT POPULATIONS AND CLINICAL VALIDATION TO ENCOURAGE GROWTH

8.3 NEUROENDOCRINE TUMORS

8.3.1 REGULATORY ADVANCEMENTS AND STRATEGIC INDUSTRY MOVES TO FACILITATE GROWTH

8.4 OTHER INDICATIONS

9 RADIOLIGAND THERAPY MARKET, BY END USER

9.1 INTRODUCTION

9.2 TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS

9.2.1 ADVANCED TREATMENT DELIVERY AND CLINICAL TRIAL CAPABILITIES TO CONTRIBUTE TO GROWTH

9.3 SPECIALIZED NUCLEAR MEDICINE CENTERS

9.3.1 HIGHLY TRAINED PERSONNEL AND TARGETED FACILITIES TO ACCELERATE GROWTH

9.4 OTHER END USERS

10 RADIOLIGAND THERAPY MARKET, BY REGION

10.1 INTRODUCTION

10.2 NORTH AMERICA

10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

10.2.2 US

10.2.2.1 Robust ecosystem of biotech innovation and strong academic-industry collaboration to spur growth.

10.2.3 CANADA

10.2.3.1 Growing clinical trial momentum to drive market

10.3 EUROPE

10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

10.3.2 GERMANY

10.3.2.1 Strong clinical advancements and active industry partnerships to foster growth.

10.3.3 UK

10.3.3.1 Growing efforts for decentralized access and innovations to boost market

10.3.4 FRANCE

10.3.4.1 Strong nuclear medicine manufacturing and isotope supply foundation to bolster growth

10.3.5 ITALY

10.3.5.1 Rising preclinical exploration and early discovery stages to stimulate growth

10.3.6 SPAIN

10.3.6.1 Established nuclear-medicine departments and authorized radiopharmacy frameworks to aid growth

10.3.7 REST OF EUROPE

10.4 ASIA PACIFIC

10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

10.4.2 CHINA

10.4.2.1 Favorable regulatory reforms and expanding hospital-based nuclear medicine capabilities to amplify growth

10.4.3 JAPAN

10.4.3.1 Academic excellence, manufacturing expansion, and supportive regulation to contribute to growth

10.4.4 INDIA

10.4.4.1 Lower trial costs and skilled medical professionals to accelerate growth

10.4.5 SOUTH KOREA

10.4.5.1 Growing emphasis on nuclear medicine innovation to propel market

10.4.6 AUSTRALIA

10.4.6.1 Need to maintain high standards of quality, compliance, and innovation to facilitate growth

10.4.7 REST OF ASIA PACIFIC

10.5 LATIN AMERICA

10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

10.5.2 BRAZIL

10.5.2.1 Favorable educational initiatives and expanding biopharma infrastructure to promote growth

10.5.3 MEXICO

10.5.3.1 Growing cyclotron capacity to fuel market

10.5.4 REST OF LATIN AMERICA

10.6 MIDDLE EAST

10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

10.6.2 GCC COUNTRIES

10.6.3 SAUDI ARABIA

10.6.3.1 Growing initiatives for healthcare and life sciences sectors to drive market

10.6.4 UAE

10.6.4.1 Emerging biotechnology sector to intensify growth

10.6.5 REST OF GCC COUNTRIES

10.6.6 REST OF MIDDLE EAST

10.7 AFRICA

10.7.1 ENHANCED CLINICAL TRIAL ECOSYSTEM AND REGULATORY REFORMS TO AID GROWTH

10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION

11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

11.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS

11.4 REVENUE ANALYSIS, 2028–2030

11.5 MARKET SHARE ANALYSIS, 2030

11.6 COMPANY VALUATION AND FINANCIAL METRICS

11.7 BRAND/PRODUCT COMPARISON

11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

11.8.1 STARS

11.8.2 EMERGING LEADERS

- 11.8.3 PERVASIVE PLAYERS
- 11.8.4 PARTICIPANTS
- 11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
 - 11.8.5.1 Region footprint
 - 11.8.5.2 Target footprint
 - 11.8.5.3 Indication footprint
- 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 - 11.9.1 PROGRESSIVE COMPANIES
 - 11.9.2 RESPONSIVE COMPANIES
 - 11.9.3 DYNAMIC COMPANIES
 - 11.9.4 STARTING BLOCKS
 - 11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 - 11.9.5.1 Detailed list of key startups/SMEs
 - 11.9.5.2 Competitive benchmarking of key startups/SMEs
- 11.10 COMPETITIVE SCENARIO
 - 11.10.1 PRODUCT LAUNCHES AND APPROVALS
 - 11.10.2 DEALS
 - 11.10.3 EXPANSIONS

12 COMPANY PROFILES

- 12.1 KEY PLAYERS
 - 12.1.1 NOVARTIS AG
 - 12.1.1.1 Business overview
 - 12.1.1.2 Products offered
 - 12.1.1.3 Products in pipeline
 - 12.1.1.4 Recent developments
 - 12.1.1.4.1 Product launches and approvals
 - 12.1.1.4.2 Deals
 - 12.1.1.4.3 Expansions
 - 12.1.1.5 MnM view
 - 12.1.1.5.1 Key strengths
 - 12.1.1.5.2 Strategic choices
 - 12.1.1.5.3 Weaknesses and competitive threats
 - 12.1.2 BAYER AG
 - 12.1.2.1 Business overview
 - 12.1.2.2 Products offered
 - 12.1.2.2.1 Deals
 - 12.1.2.2.2 Other developments

- 12.1.2.3 MnM view
 - 12.1.2.3.1 Key strengths
 - 12.1.2.3.2 Strategic choices
 - 12.1.2.3.3 Weaknesses and competitive threats
- 12.1.3 CURIUM US LLC
 - 12.1.3.1 Business overview
 - 12.1.3.2 Products in pipeline
 - 12.1.3.3 Recent developments
 - 12.1.3.3.1 Deals
 - 12.1.3.4 MnM view
 - 12.1.3.4.1 Key strengths
 - 12.1.3.4.2 Strategic choices
 - 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 ELI LILLY AND COMPANY
 - 12.1.4.1 Business overview
 - 12.1.4.2 Products in pipeline
 - 12.1.4.3 Recent developments
 - 12.1.4.3.1 Product launches and approvals
 - 12.1.4.3.2 Deals
 - 12.1.4.4 MnM view
 - 12.1.4.4.1 Key strengths
 - 12.1.4.4.2 Strategic choices
 - 12.1.4.4.3 Weaknesses and competitive threats
- 12.1.5 ASTRAZENECA
 - 12.1.5.1 Business overview
 - 12.1.5.2 Products in pipeline
 - 12.1.5.3 Recent developments
 - 12.1.5.3.1 Deals
 - 12.1.5.4 MnM view
 - 12.1.5.4.1 Key strengths
 - 12.1.5.4.2 Strategic choices
 - 12.1.5.4.3 Weaknesses and competitive threats
- 12.1.6 PROGENICS PHARMACEUTICALS INC. (LANTHEUS)
 - 12.1.6.1 Business overview
 - 12.1.6.2 Products in pipeline
 - 12.1.6.3 Recent developments
 - 12.1.6.3.1 Deals
- 12.1.7 ARICEUM THERAPEUTICS
 - 12.1.7.1 Products in pipeline

- 12.1.7.2 Recent developments
 - 12.1.7.2.1 Deals
- 12.1.8 TELIX PHARMACEUTICALS
 - 12.1.8.1 Business overview
 - 12.1.8.2 Products in pipeline
 - 12.1.8.3 Recent developments
 - 12.1.8.3.1 Deals
 - 12.1.8.3.2 Expansions
 - 12.1.8.3.3 Other developments
- 12.1.9 ITM ISOTOPE TECHNOLOGIES
 - 12.1.9.1 Business overview
 - 12.1.9.2 Products offered
 - 12.1.9.3 Recent developments
 - 12.1.9.3.1 Deals
 - 12.1.9.3.2 Expansions
- 12.1.10 CONVERGENT THERAPEUTICS, INC.
 - 12.1.10.1 Business overview
 - 12.1.10.2 Products in pipeline
 - 12.1.10.3 Recent developments
 - 12.1.10.3.1 Product launches and approvals
 - 12.1.10.3.2 Deals
- 12.1.11 ORANO SA
 - 12.1.11.1 Business overview
 - 12.1.11.2 Products in pipeline
 - 12.1.11.3 Recent developments
 - 12.1.11.3.1 Deals
 - 12.1.11.3.2 Expansions
- 12.1.12 ACTINIUM PHARMACEUTICALS, INC.
 - 12.1.12.1 Business overview
 - 12.1.12.2 Products in pipeline
 - 12.1.12.3 Recent developments
 - 12.1.12.3.1 Product launches and approvals
 - 12.1.12.3.2 Deals
- 12.1.13 PERSPECTIVE THERAPEUTICS, INC.
 - 12.1.13.1 Business overview
 - 12.1.13.2 Products in pipeline
 - 12.1.13.3 Recent developments
 - 12.1.13.3.1 Deals
- 12.1.14 CLARITY PHARMACEUTICALS

- 12.1.14.1 Business overview
- 12.1.14.2 Products in pipeline
- 12.1.14.3 Recent developments
 - 12.1.14.3.1 Deals
 - 12.1.14.3.2 Other developments
- 12.1.15 RADIOPHARM THERANOSTICS LTD.
 - 12.1.15.1 Business overview
 - 12.1.15.2 Products in pipeline
 - 12.1.15.3 Recent developments
 - 12.1.15.3.1 Deals
- 12.2 OTHER PLAYERS
 - 12.2.1 ALPHA 9 ONCOLOGY
 - 12.2.2 RATIO THERAPEUTICS
 - 12.2.3 NORIA THERAPEUTICS
 - 12.2.4 PRECIRIX
 - 12.2.5 SOFIE
 - 12.2.6 ECKERT & ZIEGLER RADIOPHARMA
 - 12.2.7 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
 - 12.2.8 IRE- IRE ELIT
 - 12.2.9 BWXT MEDICAL LTD.
 - 12.2.10 NTP RADIOISOTOPES

13 APPENDIX

- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 RADIOLIGAND THERAPY MARKET: INCLUSIONS AND EXCLUSIONS

TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS

TABLE 3 RADIOLIGAND THERAPY MARKET: RISK ANALYSIS

TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FOR
RADIOPHARMACEUTICAL MOLECULES BY REGION, 2023–2030 (USD BILLION)

TABLE 5 RADIOLIGAND THERAPY MARKET: IMPACT ANALYSIS OF MARKET
DYNAMICS

TABLE 6 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY
PRODUCTS, BY KEY PLAYER, 2024

TABLE 7 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY
PRODUCTS, BY REGION, 2024

TABLE 8 RADIOLIGAND THERAPY MARKET: ROLE OF COMPANIES IN
ECOSYSTEM

TABLE 9 RADIOLIGAND THERAPY MARKET: KEY CONFERENCES AND EVENTS,
2025–2027

TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS

TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS

TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS

TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14 RADIOLIGAND THERAPY MARKET: PORTER'S FIVE FORCES
ANALYSIS

TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
RADIOLIGAND THERAPY PRODUCTS (%)

TABLE 16 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY, BY END USER

TABLE 17 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE
OF GDP)

TABLE 18 US: CANCER INCIDENCE, BY STATE, 2024

TABLE 19 RADIOLIGAND THERAPY PRODUCTS IN CLINICAL PIPELINE, 2025–2032

TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 21 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD
MILLION)

TABLE 22 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE

TETRAKETAN, BY REGION, 2023–2035 (USD MILLION)

TABLE 23 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAKETAN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 24 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAKETAN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 25 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAKETAN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 26 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAKETAN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 27 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAKETAN, BY REGION, 2023–2035 (USD MILLION)

TABLE 28 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAKETAN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 29 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION)

TABLE 30 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 31 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 32 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 33 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 34 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION)

TABLE 35 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 36 RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION)

TABLE 37 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 38 EUROPE: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 39 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 40 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223

DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 41 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR RADIUM-223

DICHLORIDE, BY REGION, 2023–2035 (USD MILLION)

TABLE 42 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR RADIUM-223

DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 43 RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION,
2023–2035 (USD MILLION)

TABLE 44 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177
PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 45 EUROPE: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY
COUNTRY, 2023–2035 (USD MILLION)

TABLE 46 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002,
BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 47 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177
PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 48 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LU-177
PNT2002, BY REGION, 2023–2035 (USD MILLION)

TABLE 49 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LU-177
PNT2002, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 50 RADIOLIGAND THERAPY MARKET FOR 225AC-PSMA-617, BY REGION,
2023–2035 (USD MILLION)

TABLE 51 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR 225AC-
PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 52 EUROPE: RADIOLIGAND THERAPY MARKET FOR 225AC-PSMA-617, BY
COUNTRY, 2023–2035 (USD MILLION)

TABLE 53 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR 225AC-
PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 54 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR 225AC-
PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 55 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR 225AC-
PSMA-617, BY REGION, 2023–2035 (USD MILLION)

TABLE 56 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR 225AC-
PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 57 RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION,
2023–2035 (USD MILLION)

TABLE 58 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY
COUNTRY, 2023–2035 (USD MILLION)

TABLE 59 EUROPE: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY
COUNTRY, 2023–2035 (USD MILLION)

TABLE 60 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 61 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 62 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION, 2023–2035 (USD MILLION)

TABLE 63 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 64 RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION)

TABLE 65 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 66 EUROPE: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 67 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 68 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 69 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION)

TABLE 70 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 71 RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION)

TABLE 72 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 73 EUROPE: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 74 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 75 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 76 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION)

TABLE 77 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 78 RADIOLIGAND THERAPY MARKET FOR ???PB-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION)

TABLE 79 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ???PB-

DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 80 EUROPE: RADIOLIGAND THERAPY MARKET FOR ¹⁷⁷Lu-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 81 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ¹⁷⁷Lu-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 82 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ¹⁷⁷Lu-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 83 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ¹⁷⁷Lu-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION)

TABLE 84 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ¹⁷⁷Lu-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 85 RADIOLIGAND THERAPY MARKET FOR ⁶⁷Cu-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION)

TABLE 86 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ⁶⁷Cu-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 87 EUROPE: RADIOLIGAND THERAPY MARKET FOR ⁶⁷Cu-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 88 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ⁶⁷Cu-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 89 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ⁶⁷Cu-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 90 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ⁶⁷Cu-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION)

TABLE 91 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ⁶⁷Cu-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 92 RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION)

TABLE 93 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 94 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 95 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 96 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 97 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION)

TABLE 98 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 99 RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 100 RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION)

TABLE 101 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 102 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 103 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 104 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 105 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION)

TABLE 106 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 107 RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION)

TABLE 108 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 109 EUROPE: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 110 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 111 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 112 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION)

TABLE 113 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 114 RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)

TABLE 115 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 116 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 117 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 118 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER

TARGETS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 119 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)

TABLE 120 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION)

TABLE 121 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 122 RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION)

TABLE 123 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 124 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 125 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 126 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 127 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION)

TABLE 128 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 129 RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION)

TABLE 130 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 131 EUROPE: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 132 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 133 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 134 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION)

TABLE 135 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 136 RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION)

TABLE 137 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 138 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 139 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 140 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 141 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION)

TABLE 142 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 143 RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 144 RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION)

TABLE 145 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 146 EUROPE: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 147 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 148 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 149 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION)

TABLE 150 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 151 RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION)

TABLE 152 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 153 EUROPE: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED

NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 154 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 155 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 156 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION)

TABLE 157 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 158 RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION)

TABLE 159 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 160 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 161 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 162 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 163 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION)

TABLE 164 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 165 RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION)

TABLE 166 NORTH AMERICA: KEY MACROECONOMIC INDICATORS

TABLE 167 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 168 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 169 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 170 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 171 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 172 US: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035

(USD MILLION)

TABLE 173 US: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 174 US: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 175 US: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 176 CANADA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 177 CANADA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 178 CANADA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 179 CANADA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 180 EUROPE: KEY MACROECONOMIC INDICATORS

TABLE 181 EUROPE: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 182 EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 183 EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 184 EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 185 EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 186 GERMANY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 187 GERMANY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 188 GERMANY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 189 GERMANY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 190 UK: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 191 UK: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 192 UK: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035

(USD MILLION)

TABLE 193 UK: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035

(USD MILLION)

TABLE 194 FRANCE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION)

TABLE 195 FRANCE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035
(USD MILLION)

TABLE 196 FRANCE: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION)

TABLE 197 FRANCE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION)

TABLE 198 ITALY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035
(USD MILLION)

TABLE 199 ITALY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035
(USD MILLION)

TABLE 200 ITALY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035
(USD MILLION)

TABLE 201 ITALY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035
(USD MILLION)

TABLE 202 SPAIN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035
(USD MILLION)

TABLE 203 SPAIN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035
(USD MILLION)

TABLE 204 SPAIN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035
(USD MILLION)

TABLE 205 SPAIN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035
(USD MILLION)

TABLE 206 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION)

TABLE 207 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION)

TABLE 208 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY
INDICATION, 2023–2035 (USD MILLION)

TABLE 209 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION)

TABLE 210 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS

TABLE 211 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY COUNTRY,
2023–2035 (USD MILLION)

TABLE 212 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT,

2023–2035 (USD MILLION)

TABLE 213 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION)

TABLE 214 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION)

TABLE 215 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION)

TABLE 216 CHINA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035
(USD MILLION)

TABLE 217 CHINA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035
(USD MILLION)

TABLE 218 CHINA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035
(USD MILLION)

TABLE 219 CHINA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035
(USD MILLION)

TABLE 220 JAPAN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035
(USD MILLION)

TABLE 221 JAPAN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035
(USD MILLION)

TABLE 222 JAPAN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035
(USD MILLION)

TABLE 223 JAPAN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035
(USD MILLION)

TABLE 224 INDIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035
(USD MILLION)

TABLE 225 INDIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035
(USD MILLION)

TABLE 226 INDIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035
(USD MILLION)

TABLE 227 INDIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035
(USD MILLION)

TABLE 228 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY PRODUCT,
2023–2035 (USD MILLION)

TABLE 229 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY TARGET,
2023–2035 (USD MILLION)

TABLE 230 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY INDICATION,
2023–2035 (USD MILLION)

TABLE 231 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY END USER,
2023–2035 (USD MILLION)

TABLE 232 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 233 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 234 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 235 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 236 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 237 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 238 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 239 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 240 LATIN AMERICA: KEY MACROECONOMIC INDICATORS

TABLE 241 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 242 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 243 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 244 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 245 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 246 BRAZIL: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 247 BRAZIL: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 248 BRAZIL: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 249 BRAZIL: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 250 MEXICO: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 251 MEXICO: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 252 MEXICO: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 253 MEXICO: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 254 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 255 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 256 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 257 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 258 MIDDLE EAST: KEY MACROECONOMIC INDICATORS

TABLE 259 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION)

TABLE 260 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 261 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 262 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 263 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 264 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION)

TABLE 265 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 266 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 267 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 268 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 269 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 270 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 271 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 272 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 273 UAE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 274 UAE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 275 UAE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 276 UAE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 277 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 278 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 279 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 280 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 281 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 282 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 283 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 284 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 285 AFRICA: KEY MACROECONOMIC INDICATORS

TABLE 286 AFRICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION)

TABLE 287 AFRICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION)

TABLE 288 AFRICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION)

TABLE 289 AFRICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION)

TABLE 290 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOLIGAND THERAPY MARKET, 2023–2025

TABLE 291 RADIOLIGAND THERAPY MARKET: DEGREE OF COMPETITION

TABLE 292 RADIOLIGAND THERAPY MARKET: REGION FOOTPRINT

TABLE 293 RADIOLIGAND THERAPY MARKET: TARGET FOOTPRINT

TABLE 294 RADIOLIGAND THERAPY MARKET: INDICATION FOOTPRINT

TABLE 295 RADIOLIGAND THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES

TABLE 296 RADIOLIGAND THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 297 RADIOLIGAND THERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025

TABLE 298 RADIOLIGAND THERAPY MARKET: DEALS, JANUARY 2022–AUGUST 2025

TABLE 299 RADIOLIGAND THERAPY MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025

TABLE 300 NOVARTIS AG: COMPANY OVERVIEW

TABLE 301 NOVARTIS AG: PRODUCTS OFFERED

TABLE 302 NOVARTIS AG: PRODUCTS IN PIPELINE

TABLE 303 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025

TABLE 304 NOVARTIS AG: DEALS, JANUARY 2022–AUGUST 2025

TABLE 305 NOVARTIS AG: EXPANSIONS, JANUARY 2022–AUGUST 2025

TABLE 306 BAYER AG: COMPANY OVERVIEW

TABLE 307 BAYER AG: PRODUCTS OFFERED

TABLE 308 BAYER AG: DEALS, JANUARY 2022–AUGUST 2025

TABLE 309 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025

TABLE 310 CURIUM US LLC: COMPANY OVERVIEW

TABLE 311 CURIUM US LLC: PRODUCTS IN PIPELINE

TABLE 312 CURIUM US LLC: DEALS, JANUARY 2022–AUGUST 2025

TABLE 313 ELI LILLY AND COMPANY: COMPANY OVERVIEW

TABLE 314 ELI LILLY AND COMPANY: PRODUCTS IN PIPELINE

TABLE 315 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– AUGUST 2025

TABLE 316 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–AUGUST 2025

TABLE 317 ASTRAZENECA: COMPANY OVERVIEW

TABLE 318 ASTRAZENECA: PRODUCTS IN PIPELINE

TABLE 319 ASTRAZENECA: DEALS, JANUARY 2022–AUGUST 2025

TABLE 320 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY OVERVIEW

TABLE 321 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): PRODUCTS IN PIPELINE

TABLE 322 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): DEALS, JANUARY

2022–AUGUST 2025

TABLE 323 ARICEUM THERAPEUTICS: COMPANY OVERVIEW

TABLE 324 ARICEUM THERAPEUTICS: PRODUCTS IN PIPELINE

TABLE 325 ARICEUM THERAPEUTICS: DEALS, JANUARY 2022–AUGUST 2025

TABLE 326 TELIX PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 327 TELIX PHARMACEUTICALS: PRODUCTS IN PIPELINE

TABLE 328 TELIX PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025

TABLE 329 TELIX PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–AUGUST 2025

TABLE 330 TELIX PHARMACEUTICAL: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025

TABLE 331 ITM ISOTOPE TECHNOLOGIES: COMPANY OVERVIEW

TABLE 332 ITM ISOTOPE TECHNOLOGIES: PRODUCTS OFFERED

TABLE 333 ITM ISOTOPE TECHNOLOGIES: DEALS, JANUARY 2022–AUGUST 2025

TABLE 334 ITM ISOTOPE TECHNOLOGIES: EXPANSIONS, JANUARY 2022–AUGUST 2025

TABLE 335 CONVERGENT THERAPEUTICS, INC.: COMPANY OVERVIEW

TABLE 336 CONVERGENT THERAPEUTICS, INC.: PRODUCTS IN PIPELINE

TABLE 337 CONVERGENT THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025

TABLE 338 CONVERGENT THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025

TABLE 339 ORANO SA: COMPANY OVERVIEW

TABLE 340 ORANO SA: PRODUCTS IN PIPELINE

TABLE 341 ORANO SA: DEALS, JANUARY 2022–AUGUST 2025

TABLE 342 ORANO SA: EXPANSIONS, JANUARY 2022–AUGUST 2025

TABLE 343 ACTINIUM PHARMACEUTICALS, INC.: COMPANY OVERVIEW

TABLE 344 ACTINIUM PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE

TABLE 345 ACTINIUM PHARMACEUTICALS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025

TABLE 346 ACTINIUM PHARMACEUTICALS, INC.: DEALS, JANUARY 2022–AUGUST 2025

TABLE 347 PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW

TABLE 348 PERSPECTIVE THERAPEUTICS, INC.: PRODUCTS IN PIPELINE

TABLE 349 PERSPECTIVE THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025

TABLE 350 CLARITY PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 351 CLARITY PHARMACEUTICALS: PRODUCTS IN PIPELINE

TABLE 352 CLARITY PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025

TABLE 353 CLARITY PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025

TABLE 354 RADIOPHARM THERANOSTICS LTD.: COMPANY OVERVIEW

TABLE 355 RADIOPHARM THERANOSTICS LTD.: PRODUCTS IN PIPELINE

TABLE 356 RADIOPHARM THERANOSTICS LTD.: DEALS, JANUARY 2022–AUGUST 2025

TABLE 357 ALPHA 9 ONCOLOGY: COMPANY OVERVIEW

TABLE 358 RATIO THERAPEUTICS: COMPANY OVERVIEW

TABLE 359 NORIA THERAPEUTICS: COMPANY OVERVIEW

TABLE 360 PRECIRIX: COMPANY OVERVIEW

TABLE 361 SOFIE: COMPANY OVERVIEW

TABLE 362 ECKERT & ZIEGLER RADIOPHARMA: COMPANY OVERVIEW

TABLE 363 NORTHSTAR MEDICAL RADIOISOTOPES, LLC: COMPANY OVERVIEW

TABLE 364 IRE- IRE ELIT: COMPANY OVERVIEW

TABLE 365 BWXT MEDICAL LTD.: COMPANY OVERVIEW

TABLE 366 NTP RADIOISOTOPES: COMPANY OVERVIEW

List Of Figures

LIST OF FIGURES

FIGURE 1 RADIOLIGAND THERAPY MARKET SEGMENTATION AND REGIONAL SCOPE

FIGURE 2 RADIOLIGAND THERAPY MARKET: YEARS CONSIDERED

FIGURE 3 RADIOLIGAND THERAPY MARKET: RESEARCH DESIGN

FIGURE 4 RADIOLIGAND THERAPY MARKET: KEY DATA FROM SECONDARY SOURCES

FIGURE 5 RADIOLIGAND THERAPY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS

FIGURE 6 RADIOLIGAND THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030

FIGURE 8 REVENUE SHARE ANALYSIS OF NOVARTIS, 2024

FIGURE 9 RADIOLIGAND THERAPY MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 10 RADIOLIGAND THERAPY MARKET: TOP-DOWN APPROACH

FIGURE 11 RADIOLIGAND THERAPY MARKET: CAGR PROJECTIONS

FIGURE 12 RADIOLIGAND THERAPY MARKET: DATA TRIANGULATION

FIGURE 13 RADIOLIGAND THERAPY MARKET: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

FIGURE 14 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2025 VS. 2035 (USD MILLION)

FIGURE 15 RADIOLIGAND THERAPY MARKET, BY TARGET, 2025 VS. 2035 (USD MILLION)

FIGURE 16 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION)

FIGURE 17 RADIOLIGAND THERAPY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION)

FIGURE 18 GEOGRAPHICAL SNAPSHOT OF RADIOLIGAND THERAPY MARKET

FIGURE 19 INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS TO DRIVE MARKET

FIGURE 20 LUTETIUM-177 VIPIVOTIDE TETRAXETAN SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2024

FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

FIGURE 22 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATE

DURING FORECAST PERIOD

FIGURE 23 RADIOLIGAND THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 24 NEW REVENUE POCKETS FOR PLAYERS IN RADIOLIGAND THERAPY MARKET

FIGURE 25 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024

FIGURE 26 INDICATIVE PRICING ANALYSIS, BY REGION, 2024

FIGURE 27 RADIOLIGAND THERAPY MARKET: VALUE CHAIN ANALYSIS

FIGURE 28 RADIOLIGAND THERAPY MARKET: ECOSYSTEM ANALYSIS

FIGURE 29 RADIOLIGAND THERAPY MARKET: INVESTMENT AND FUNDING SCENARIO, 2023–2024

FIGURE 30 RADIOLIGAND THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND THERAPY PRODUCTS

FIGURE 32 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY PRODUCTS, BY END USER

FIGURE 33 RADIOLIGAND THERAPY MARKET: AI USE CASES

FIGURE 34 NORTH AMERICA: RADIOLIGAND THERAPY MARKET SNAPSHOT

FIGURE 35 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET SNAPSHOT

FIGURE 36 RADIOLIGAND THERAPY MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2028–2030 (USD MILLION)

FIGURE 37 RADIOLIGAND THERAPY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2030

FIGURE 38 EV/EBITDA OF KEY VENDORS

FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 40 RADIOLIGAND THERAPY MARKET: BRAND/PRODUCT COMPARISON

FIGURE 41 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 42 RADIOLIGAND THERAPY MARKET: COMPANY FOOTPRINT

FIGURE 43 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024)

FIGURE 45 BAYER AG: COMPANY SNAPSHOT (2024)

FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)

FIGURE 47 ASTRAZENECA: COMPANY SNAPSHOT (2024)

FIGURE 48 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY

SNAPSHOT (2024)

FIGURE 49 TELIX PHARMACEUTICALS: COMPANY SNAPSHOT (2024)

FIGURE 50 ORANO SA: COMPANY SNAPSHOT (2024)

FIGURE 51 ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)

FIGURE 52 CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT (2024)

I would like to order

Product name: Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

Product link: <https://marketpublishers.com/r/R9C902B6A81CEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R9C902B6A81CEN.html>